


Epilepsia™

Official Journal of the International League Against Epilepsy

International Epilepsy Congress Abstract Issue



WILEY

wileyonlinelibrary.com/journal/epi



International League
Against Epilepsy

EpilepsiaTM

Official Journal of the International League Against Epilepsy

Volume 64, Supplement 2, November 2023

Cover

Cover image credit: Mesa Schumacher

This journal is listed in Index Medicus/MEDLINE, Current Contents/Life Sciences, Current Contents/Clinical Medicine, Neuroscience Citation Index, Reference Update, Science Citation Index, SciSearch/SCI Expanded, EMBASE/Excerpta Medica, Biological Abstracts, Chemical Abstracts Databases, Global Health, Derwent Journals Abstracted, PsychInfo/ Psychological Abstracts, BIOSIS, PASCAL, EBSCO, and CABS.

Epilepsia is a member of the Committee on Publication Ethics (COPE)

C O P E COMMITTEE ON PUBLICATION ETHICS

Disclaimer

The Publisher, the International League Against Epilepsy, and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher, International League Against Epilepsy, or Editors, neither does the publication of advertisements constitute any endorsement by the Publisher, International League Against Epilepsy, or Editors of the products advertised.

Copyright and Copying

Copyright © 2023 International League Against Epilepsy. All rights reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Special requests should be addressed to: permissions@wiley.com

Information for subscribers

Epilepsia is published in 12 issues per year. Institutional subscription prices for 2022 are:

Print & Online: US\$2893 (US), US\$3944 (Rest of World), €2558 (Europe), £2016 (UK). Prices are exclusive of tax. Asia-Pacific GST, Canadian GST/HST and European VAT will be applied at the appropriate rates. For more information on current tax rates, please go to <https://onlinelibrary.wiley.com/library-info/products/price-lists/payment>. The price includes online access to the current and all online back files for previous 5 years, where available. For other pricing options, including access information and terms and conditions, please visit <https://onlinelibrary.wiley.com/library-info/products/price-lists>. Terms of use can be found here: <https://onlinelibrary.wiley.com/terms-and-conditions>

Delivery Terms and Legal Title

Where the subscription price includes print issues and delivery is to the recipient's address, delivery terms are Delivered at Place (DAP); the recipient is responsible for paying any import duty or taxes. Title to all issues transfers FOB our shipping point, freight prepaid.

Claims for Missing or Damaged Print Issues

Our policy is to replace missing or damaged copies within our reasonable discretion, subject to print issue availability, and subject to the following terms: Title to all issues transfers Freight on Board ("FOB") to the address specified in the order; (1) Freight costs are prepaid by Wiley; and (2) Claims for missing or damaged copies must be submitted by the Customer or Subscription Agent within the claims window, as noted below.

Claims window - General

Claims for missing print issues must be sent to cs-agency@wiley.com (and the Subscription Agent or Customer may be referred to a society) within three months of whichever of these dates is the most recent: date of subscription payment; or date of issue publication.

Claims window - India

Both Subscription Agents and Customers in India have 48 hours after receipt of goods to confirm that all content listed on the packing label has been received. In the event of any discrepancy, SPUR Infosolutions, Wiley's delivery partner in India, needs to be notified within forty-eight (48) hours using this email address: support@spurinfo.com. All claims will be checked against SPUR Infosolutions delivery records before the claim is accepted. The above terms for Wiley's claims policy otherwise apply.

Back issues: Single issues from current and recent volumes are available at the current single issue price from cs-journals@wiley.com. Earlier issues may be obtained from Periodicals Service Company, 351 Fairview Avenue - Ste 300, Hudson, NY 12534, USA. Tel: +1 518 822-9300, Fax: +1 518 822-9305, Email: psc@periodicals.com
Epilepsia, (ISSN 0013-9580 [print] ISSN 1528-1167 [online]), is published monthly on behalf of the International League Against Epilepsy by Wiley Periodicals LLC, 111 River St., Hoboken, NJ 07030-5774.

Periodical Postage Paid at Hoboken, NJ and additional offices.

Postmaster: Send all address changes to EPILEPSIA, Wiley Periodicals LLC, C/O The Sheridan Press, PO Box 465, Hanover, PA 17331.

Publisher

Epilepsia is published by Wiley Periodicals LLC 101 Station Landing, Suite 300, Medford, MA 02155

Journal Customer Services: For ordering information, claims and any enquiry concerning your journal subscription please go to <https://wolsupport.wiley.com/s/contactsupport?tabset-a7d10=2> or contact your nearest office.

Americas: Email: cs-journals@wiley.com; Tel: +1 877 762 2974.

Europe, Middle East and Africa: Email: cs-journals@wiley.com; Tel: +44 (0) 1865 778315; 0800 1800 536 (Germany).

Germany, Austria, Switzerland, Luxembourg, Liechtenstein: cs-germany@wiley.com; Tel: 0800 1800 536 (Germany)

Asia Pacific: Email: cs-journals@wiley.com; Tel: +65 3165 0890.

Japan: For Japanese speaking support, Email: cs-japan@wiley.com.

Visit our Online Customer Help at <https://wolsupport.wiley.com/s/contactsupport?tabset-a7d10=2>

Production Editor: Vikranth Parthibhan (email: epi@wiley.com)

Advertising: For information on advertising, contact Kathleen Harrison, PMI, 212-904-0372, kharrison@pminy.com

Commercial reprints: Helane Silverman (email: hsilverman@wiley.com)

View this journal online at onlinelibrary.wiley.com/journal/epi

Wiley is a founding member of the UN-backed HINARI, AGORA, and OARE initiatives. They are now collectively known as Research4Life, making online scientific content available free or at nominal cost to researchers in developing countries. Please visit Wiley's Content Access - Corporate Citizenship site: <http://www.wiley.com/WileyCDA/Section/id-390082.html> Printed in the United States by The Sheridan Group.

Wiley's Corporate Citizenship initiative seeks to address the environmental, social, economic, and ethical challenges faced in our business and which are important to our diverse stakeholder groups. Since launching the initiative, we have focused on sharing our content with those in need, enhancing community philanthropy, reducing our carbon impact, creating global guidelines and best practices for paper use, establishing a vendor code of ethics, and engaging our colleagues and other stakeholders in our efforts.

Follow our progress at www.wiley.com/go/citizenship

Epilepsia accepts articles for Open Access publication. Please visit <https://authorservices.wiley.com/Author-resources/Journal-Authors/open-access/hybrid-open-access.html> for further information about OnlineOpen.

For submission instructions, subscription and all other information visit: <http://www.epilepsia.com>

EpilepsiaTM

Official Journal of the International League Against Epilepsy

<http://www.epilepsia.com>

EDITOR-IN-CHIEF

Michael R. Sperling, MD
Thomas Jefferson University
Philadelphia, PA, USA

DEPUTY EDITOR

Stéphane Auvin, MD, PhD
University of Paris
Paris, France

ASSOCIATE EDITORS

Heinz Beck

Bonn, Germany

Gregory D. Cascino

Rochester, MN, USA

Fernando Cendes

Campinas, SP, Brazil

Alica M. Goldman

Houston, TX, USA

Julia Jacobs

Freiburg, Germany

Martin Holtkamp

Berlin, Germany

Nathalie Jetté

New York, NY, USA

David W. Loring

Atlanta, GA, USA

Philip N. Patsalos

London, United Kingdom

Annapurna Poduri

Boston, MA, USA

Heidrun Potschka

Munich, Germany

Prabha Siddarth

Los Angeles, CA, USA

Jo M. Wilmshurst

Cape Town, South Africa

EDITORIAL BOARD

Danielle Andrade

Toronto, ON, Canada

Marion Bankstahl

Hannover, Germany

Sándor Beniczky

Aarhus, Denmark

Leonardo Bonilha

Charleston, SC, USA

Karin Borges

Brisbane, QLD, Australia

Roberto Caraballo

Buenos Aires, Argentina

Mark J. Cook

Melbourne, VIC, Australia

Ding Ding

Shanghai, China

Patrick Forcelli

Washington, DC, USA

Keiko Hara

Tokyo, Japan

W. Allen Hauser

New York, NY, USA

Barbara Jobst

Hanover, NH, USA

Cecilie Johannessen

Oslo, Norway

Nigel Jones

Melbourne, VIC,

Australia

Csaba Juhasz

Detroit, MI, USA

Dorothee Kasteleijn-

Noslé Trenité

Utrecht, Netherlands

Mark Keezer

Montreal, QB,
Canada

Katja Kobow

Erlangen, Germany

Dennis Lal

Cleveland, OH, USA

Holger Lerche

Tübingen, Germany

Wolfgang Löscher

Hannover, Germany

Nicola Marchi

Montpellier, France

Mathieu Milh

Marseille, France

Maromi Nei

Philadelphia, PA,
USA

Filiz Onat

Istanbul, Turkey

Pasquale Parisi

Rome, Italy

Sylvain Rheims

Lyon, France

Andreas Schulze-

Bonhage

Freiburg, Germany

Bernhard Steinhoff

Kehl-Kork, Germany

Roland Thijs

Heemstede, The Netherlands

Manjari Tripathi

Delhi, DL, India

Erwin van Vliet

Amsterdam, Netherlands

Jana Veliskova

New York, NY, USA

Janelle Wagner

Charleston, SC, USA

Elaine Wirrell

Rochester, MN, USA

ILAE EXECUTIVE COMMITTEE

J. Helen Cross

President/Congress Council

chair, United Kingdom

Roberto Horacio Caraballo

Vice President, Argentina

Alla Guekht

Treasurer/Global Advocacy

Council Chair, Russian

Federation

Edward H. Bertram, III

Secretary General, USA

Samuel Wiebe

Past President, Canada

Gagandeep Singh

Chair, Education Council,

Germany

Michael Sperling

Chair, Publication Council,

Canada

Nathalie Jetté

Chair, Standards & Best

Practice Council, USA

Jo M Wilmshurst

Chair, ILAE-Africa,

South Africa

John W. Dunne

Chair, ILAE-Asia & Oceania,

Australia

Ghaieb Bashar Mohamed

Chair, ILAE-Eastern

Mediterranean, Iraq

Matthew Walker

Chair, ILAE-Europe,

United Kingdom

Mario Alonso-Vanegas

Chair, ILAE-Latin America,

México

Jaideep Kapur

Chair, ILAE-North America,

USA

Eugen Trinko

Strategic Advisor, Austria

Julie Hall

ILAE Executive Director,

United Kingdom

Francesca Sofia

IBE President, Italy

Gus A Baker

IBE Secretary- General,

United Kingdom

Graeme Shears

IBE Treasurer, Australia

EDITORIAL AND PRODUCTION STAFF

MANAGING EDITOR

Laurie Benisig
epilepsia@ilae.org

PRODUCTION EDITOR

Vikranth Parthibhan
EPI@wiley.com

ASSOCIATE EDITORIAL DIRECTOR

Cathy Krendel
Wiley
Hoboken, NJ 07030

EpilepsiaTM

Official Journal of the International League Against Epilepsy

Volume 64, Supplement 2, November 2023

International Epilepsy Congress Abstract Issue

TABLE OF CONTENTS

Volume 64, Supplement 2, November 2023

SUPPLEMENT ARTICLES

1
Satellite Symposium
doi: 10.1111/epi.17786

7
Abstracts
doi: 10.1111/epi.17787

571
Author Index
doi: 10.1111/epi.17788

1121 | Evaluation of the effectiveness of topiramate in the treatment of epilepsy in women of reproductive age

F Muratov¹, D Yusupova¹

¹Tashkent medical academy, Tashkent, Uzbekistan

Purpose: To evaluate the effectiveness of topiramate in the treatment of epilepsy in women of reproductive age.

Method: 78 women were examined, aged 18 to 52 years. The mean age of the patients was 28.6 ± 11.4 years. To optimize therapy, taking into account the minimal effect of topiramate on the development of oncological diseases of the female reproductive system, we made a gradual replacement of the anticonvulsant drug valproic acid to topiramate at the rate of 3-5 mg/kg of body weight per day. At the same time, the average daily the dose did not exceed 200 mg/day.

Results: After 6 months of regular intake of topiramates at a dosage of 200 mg/day in group 1 patients, a decrease in the frequency of attacks from 8-10 to 5 attacks per month was noted. The dynamics of attacks was the best at 3-6 months of taking topiramate, and reached 1 attack per month by 6 months. In addition, patients noted a decrease in the duration of seizures up to 1 minute, with initial values up to 3-5 minutes. In group 2, we also noted a decrease in the frequency of seizures up to 3-4 times a month, however, the dynamics was lower than in group 1 group. Whereas in group 2, against the background of the drug valproic acid, an increase in the content of progesterone was not observed.

Conclusion: Against the background of topiramate in the group of patients with resistant the course of epilepsy, the values of estradiol were initially higher than those of progesterone. At the same time, in group 2, our studies showed the absence of a positive effect of valproic acid on the change in the progesterone / estradiol ratio, which maintained an insufficient level of clinical compensation for seizures in group 2 patients.

Epilepsy in Older People

272 | Idiopathic generalized epilepsies in elderly: young features on old background

D Dragan¹

¹State University of Medicine and Pharmacy Nicolae Testemitanu, Neurobiology and medical genetics laboratory, Chisinau, Moldova, Republic of

Purpose: Idiopathic generalized epilepsies (IGEs) are most commonly seen in children, adolescents and young adults, with well-defined criteria and management. Much less is known about its occurrence in the elderly, and

generalized epilepsy has traditionally been thought to rarely develop as a new-onset seizure disorder in this age group. In this study, we purpose to identify common features of IGEs in elderly patients.

Method: This is a retrospective study on 370 elderly patients (mean age 70.25 ± 5.73 years) with epilepsy referred by a neurologist to our epilepsy center and followed between 2018 – 2022 at the National Epilepsy Center, Republic of Moldova. The patients were examined with a detailed medical history, neurological examination, EEG and neuroimaging.

Results: In our population, IGEs in the elderly people account about 4.05% (15 elderly patients). Patients were diagnosed with IGEs based on clinical semiology of seizures (myoclonic seizures, absence seizures and tonic – clonic seizure on awakening) in 3 patients (20%), and in the rest of them, exclusively diagnosed based on video EEG recording of seizures (myoclonic seizures) and interictal generalized discharged (bilateral synchronous spike and waves, or polyspikes and waves epileptiform discharges). The mean aged of seizures onset was at 16.66 ± 8.05 years old, with an unusual case of seizures onset at 68 years old, and was common long term seizure freedom (21.5 ± 7.93 years of remission). On neuroimaging all patients presented mild diffuse subcortical gliosis (Fazekas I), and 1 patient with parietal cavernoma.

Conclusion: In 80% of cases IGEs in elderly is diagnosed by EEG and they commonly are associated with frequent non-specific structural cerebral lesions and long-term seizure freedom during life time. Clinically, elderly with IGEs exhibit same seizure types like other age groups.

343 | Epilepsy in the elderly: clinical and therapeutic characteristics

V Roig^{1,2,3}, V Ibarra^{4,3}, O Lina⁴, S Keila⁴, S Keyla⁴, G Ronald⁴, E Hugo⁴, G Natalia^{4,3}, T Carlos^{4,3,5}

¹Sanatorio Mendez, Neurology, Buenos Aires, Argentina, ²INEBA, Epilepsy, Buenos Aires, Argentina, ³Universidad de Buenos Aires, Buenos Aires, Argentina, ⁴Sanatorio Mendez, Buenos Aires, Argentina, ⁵Hospital Naval, Buenos Aires, Argentina

Purpose: The incidence of epilepsy in people older than 60 years is higher when compared with younger populations. They have unique clinical, etiologic and therapeutic characteristics. We aim to analyze elderly people with epilepsy since there are few research works in our country.

Method: We searched all electronic medical records from January 2015 to December 2022 of our clinic. We found 511 patients with epilepsy, 198 were older than 60 years at last visit and we identify 93 patients with epilepsy onset after that age.